Pediatric disclosure of HIV status and effect on mortality and LTFU among children and adolescents living with HIV in Asia

APACC 2021

Psychosocial Risk Factors and Cognitive Decline in People Living with HIV: Results from the Malaysian HIV and Aging (MHIVA) Study

APACC 2021

Self-sampled specimens demonstrate comparable sensitivity and specificity to clinician-sampled specimens for HPV detection among MSM in China

APACC 2021

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfected Patients Through 96 Weeks

APACC 2021

APACC 2022

Russian HIV Clinical Series | Roundtable Discussion | 3rd Edition | 13 May

Russian HIV Clinical Series 2021

Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Lost in translation: learning from preclinical data | Gerry Davies

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Russian HIV Clinical Series | Natalia Litvinova | 2nd Edition | 15 April

Russian HIV Clinical Series 2021

Benefits of data collaboration – personalized tailoring regimens | Rada Savic, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents | Alexander Berg, PharmD, PhD, FCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

Searching for a Universal Regimen for Tuberculosis Treatment with a Shorter Duration of Therapy | Khisi Mdluli, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

Abstract: Integrated testing and integrated diagnostic platforms of Hepatitis B and C with HIV and TB in Rwanda | Jean Damascene Makuza

International Viral Hepatitis Elimination Meeting (IVHEM) 2018

Gertrude Elion Distinguished Lecturer Award Lecture: Innovation with an Impact: Development of HIV and TB drugs | Paul Stoffels, MD

HIV DART and Emerging Viruses 2018

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

CPK/PD Support for a Phase 1 Study of TBA-7371- Jerry Nedelman, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect- Lénaïg Tanneau, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

TPreclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid- Suresh Mallikaarjun, PHD, FCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline- An Vermeulen, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention- Anthony Podany, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB- Andrew McCallum, MBChB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018